TNYA vs. ADAP, QURE, PGEN, ABSI, BCAB, AUTL, IMTX, TARS, HUMA, and MESO
Should you be buying Tenaya Therapeutics stock or one of its competitors? The main competitors of Tenaya Therapeutics include Adaptimmune Therapeutics (ADAP), uniQure (QURE), Precigen (PGEN), Absci (ABSI), BioAtla (BCAB), Autolus Therapeutics (AUTL), Immatics (IMTX), Tarsus Pharmaceuticals (TARS), Humacyte (HUMA), and Mesoblast (MESO). These companies are all part of the "medical" sector.
Tenaya Therapeutics (NASDAQ:TNYA) and Adaptimmune Therapeutics (NASDAQ:ADAP) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation, profitability and community ranking.
Tenaya Therapeutics has a beta of 2.42, indicating that its share price is 142% more volatile than the S&P 500. Comparatively, Adaptimmune Therapeutics has a beta of 2.31, indicating that its share price is 131% more volatile than the S&P 500.
Tenaya Therapeutics currently has a consensus target price of $15.00, indicating a potential upside of 286.60%. Adaptimmune Therapeutics has a consensus target price of $2.79, indicating a potential upside of 100.54%. Given Tenaya Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Tenaya Therapeutics is more favorable than Adaptimmune Therapeutics.
Adaptimmune Therapeutics has higher revenue and earnings than Tenaya Therapeutics. Tenaya Therapeutics is trading at a lower price-to-earnings ratio than Adaptimmune Therapeutics, indicating that it is currently the more affordable of the two stocks.
Adaptimmune Therapeutics received 282 more outperform votes than Tenaya Therapeutics when rated by MarketBeat users. However, 77.14% of users gave Tenaya Therapeutics an outperform vote while only 62.42% of users gave Adaptimmune Therapeutics an outperform vote.
Tenaya Therapeutics has a net margin of 0.00% compared to Adaptimmune Therapeutics' net margin of -890.13%. Tenaya Therapeutics' return on equity of -76.38% beat Adaptimmune Therapeutics' return on equity.
90.5% of Tenaya Therapeutics shares are held by institutional investors. Comparatively, 31.4% of Adaptimmune Therapeutics shares are held by institutional investors. 32.8% of Tenaya Therapeutics shares are held by insiders. Comparatively, 12.4% of Adaptimmune Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Tenaya Therapeutics had 2 more articles in the media than Adaptimmune Therapeutics. MarketBeat recorded 4 mentions for Tenaya Therapeutics and 2 mentions for Adaptimmune Therapeutics. Adaptimmune Therapeutics' average media sentiment score of 1.26 beat Tenaya Therapeutics' score of 0.73 indicating that Adaptimmune Therapeutics is being referred to more favorably in the news media.
Summary
Tenaya Therapeutics beats Adaptimmune Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Tenaya Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TNYA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TNYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tenaya Therapeutics Competitors List
Related Companies and Tools
